The consistent upregulation of Trem2, Anxa2, Ttc39a, and Gdf15 across all stages of liver disease—from steatosis and NASH to fibrosis—suggests that these genes play a pivotal role in the progression of NAFLD. Here, ANXA2 is linked to metabolic dysfunction-associated steatohepatitis.